BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 8701189)

  • 1. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
    Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
    Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the cardiac renin-angiotensin system in hypertensive heart disease].
    Holmer SR; Riegger GA
    Herz; 1995 Oct; 20(5):322-9. PubMed ID: 7498879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S; Burkhoff D; Garrelds IM; Boomsma F; Danser AH
    Eur Heart J; 2009 Apr; 30(7):805-12. PubMed ID: 19223317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology of left ventricular hypertrophy in arterial hypertension].
    Vallotton MB; Braconi-Quintaje S; Lang U
    Praxis (Bern 1994); 1997 Feb; 86(7):234-7. PubMed ID: 9139339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
    Falkenhahn M; Gohlke P; Paul M; Stoll M; Unger T
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S6-13. PubMed ID: 7898096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac renin-angiotensin system: role in development of pressure-overload hypertrophy.
    Lorell BH
    Can J Cardiol; 1995 Aug; 11 Suppl F():7F-12F. PubMed ID: 7664219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms.
    Weber KT; Sun Y; Tyagi SC; Cleutjens JP
    J Mol Cell Cardiol; 1994 Mar; 26(3):279-92. PubMed ID: 8028011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertensive heart disease].
    Funck RC; Wilke A; Rupp H; Maisch B; Brilla CG
    Herz; 1995 Oct; 20(5):330-9. PubMed ID: 7498880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.